Using immune cell therapy to treat brain tumors.
Immuno-Cell Therapy for Brain Tumors
This study is testing a new treatment for glioblastoma, a tough brain tumor, by using special immune cells to attack both the tumor and the stubborn cells that help it come back, with the hope of giving patients a better chance at recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11004346 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for glioblastoma, a highly aggressive brain tumor with a very low survival rate. The approach involves using immune cells to target not only the tumor cells but also the resistant stem-like cells that contribute to tumor recurrence. By harnessing the unique properties of olfactory ensheathing cells, which can promote neural regeneration, the research aims to create a therapy that is more effective than current standard treatments. Patients may receive this innovative therapy as part of their treatment plan, potentially improving their outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who have not responded well to standard treatments.
Not a fit: Patients with brain tumors other than glioblastoma or those who are not eligible for immune cell therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of life for patients with glioblastoma.
How similar studies have performed: Other research has shown promising results using immune cell therapies for various cancers, suggesting potential success for this novel approach in treating glioblastoma.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Breakefield, Xandra Owens — Massachusetts General Hospital
- Study coordinator: Breakefield, Xandra Owens
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.